Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11545
Title: Hypocalcemia induced by raloxifene.
Authors: Vu, Thuy D T;Varadarajan, Suresh;Seeman, Ego;Jerums, George;MacIsaac, Richard J
Affiliation: Endocrinology Department, Austin Health, Victoria, Australia. thuy.vu@austin.org.au
Issue Date: 1-Apr-2012
Citation: Current Drug Safety; 7(2): 176-8
Abstract: Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
Internal ID Number: 22873502
URI: http://ahro.austin.org.au/austinjspui/handle/1/11545
URL: http://www.ncbi.nlm.nih.gov/pubmed/22873502
Type: Journal Article
Subjects: Aged, 80 and over
Bone Density Conservation Agents.adverse effects.therapeutic use
Female
Humans
Hypocalcemia.chemically induced
Mass Screening.methods
Osteoporosis, Postmenopausal.drug therapy
Raloxifene.adverse effects.therapeutic use
Vitamin D Deficiency.complications.diagnosis
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.